Hyperbaric oxygen therapy for traumatic brain injury: bench-to-bedside

Qin Hu1, 2, Anatol Manaenko2, Ting Xu2, Zhenni Guo2, Jiping Tang2, John H. Zhang2, 3, *

1 Discipline of Neuroscience, Department of Anatomy, Histology and Embryology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Departments of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA, USA
3 Department of Neurosurgery, Loma Linda University School of Medicine, Loma Linda, CA, USA

*Correspondence to: John H. Zhang, M.D., Ph.D., johnzhang3910@yahoo.com.

Abstract

Traumatic brain injury (TBI) is a serious public health problem in the United States. Survivors of TBI are often left with significant cognitive, behavioral, and communicative disabilities. So far there is no effective treatment/intervention in the daily clinical practice for TBI patients. The protective effects of hyperbaric oxygen therapy (HBOT) have been proved in stroke; however, its efficiency in TBI remains controversial. In this review, we will summarize the results of HBOT in experimental and clinical TBI, elaborate the mechanisms, and bring out our current understanding and opinions for future studies.

Key words: traumatic brain injury; hyperbaric oxygen therapy; tissue oxygenation; inflammation; apoptosis

doi: 10.4103/2045-9912.184720


INTRODUCTION

Traumatic brain injury (TBI) is an insult or trauma to the brain caused by external mechanical forces. With an estimated 10 million people affected annually by TBI in the United States, the burden of mortality and morbidity that this condition imposes on society, makes TBI a pressing public health and medical problem (Hyder et al., 2007). The damage caused by TBI can be focal (confined to one area of the brain) or diffuse (involving more than one area of the brain) (Zhang et al., 2014b). Symptoms of a TBI vary from mild and moderate to severe, depending on the extent of the damage to the brain. Survivors of TBI are often left with significant cognitive, behavioral, and communicative disabilities (Sun et al., 2015; Xiao et al., 2015), and there is no effective treatment/intervention in the daily clinical practice for TBI patients. There are three distinct yet over-lapping pathophysiological states of TBI: acute, subacute and chronic phases. The acute phase usually occurs within 24 hours of injury, the subacute phase takes place in days following TBI, and the chronic phase arises days to weeks after TBI (Algattas and Huang, 2014). The pathophysiology after TBI has a primary and secondary component (Kolias et al., 2013). At the time of impact there is a variable degree of irreversible damage to the brain tissue (primary injury). Following this, a chain of events occurs in which there is ongoing injury to the brain through edema, hypoxia and ischemia secondary to raised intracranial pressure, release of excitotoxic neurotransmitters and impaired calcium homeostasis (secondary injury) (Algattas and Huang, 2014). There is no option to interfere with the primary injury other than prevention of the trauma itself; however, investigations on the secondary injury in TBI are helpful for the identification of therapeutic targets for TBI.

Hyperbaric oxygen therapy (HBOT) is defined as the inhalation of 100% oxygen under the pressure greater than 1 atmosphere absolute (ATA) (1 ATA = 101.3 kPa). HBOT is a current interest in the field of neurological diseases and has been proved to inhibit apoptosis, suppress inflammation, protect the integrity of blood-brain barrier, and...
The application of hyperbaric oxygen (HBO) in treatment of TBI started in 1960s. The first study reporting the neuroprotection of HBO in experimental brain injury in rats was published in 1966 (Coe and Hayes, 1966). At the same year, Dunn and Lawson demonstrated that HBO significantly improved outcomes and reduced mortality in a dog freeze-lesion model of brain injury that simulated a brain contusion (Dunn et al., 1966). In the following years, several experimental studies focusing on the effects of HBO on brain edema, intracranial pressure (ICP) and cerebral blood flow (CBF) appeared (Table 1). Hollin et al. (1968) reported that in dogs using HBO at 3 ATA for 45 minutes resulted in less brain edema and a significant decrease (>50%) in mortality compared to non-treated injured animals. In psyllium seed induced brain edema model in dogs, HBOT at 2 ATA for 4 hours reduced cerebrospinal fluid (CSF) pressure and protected brain against ischemia (Sukoff et al., 1968). HBOT at 2 ATA for 4 hours decreased ICP by 30% and CBF by 19% (Miller et al., 1970), and failed to affect the CSF lactate in a dog model of brain injury (Miller and Ledingham, 1971).

The neuroprotective effects of HBO have been also demonstrated during the acute phase, within 24 hours after TBI. In the rat model of dynamic cortical deformation, HBOT (2.8 ATA for two consecutive sessions of 45 minutes each) starting at 3 hours after injury significantly decreased apoptosis and reduced the severity and extent of secondary brain damage (Palzur et al., 2004). The neuroprotective effects of HBOT were mediated by inhibition of the mitochondrial permeability transition pore (Palzur et al., 2008). In the same model, HBO also reduced neuroinflammation and the expression of matrix metalloproteinase-9 (Vlodavsky et al., 2006). In the controlled cortical impact model of TBI on mice, HBOT (2.0 ATA for 1 hour) administrated 3 hours post-injury increased the level of interleukin-10, resulting in reduced lesion volume, attenuated cerebral edema and improved neurological status (Chen et al., 2014). The therapeutic time window of HBO was further investigated in animal models of TBI. In the early stage of TBI, 3-day HBOT (2.0 ATA for 60 minutes daily, started 3 hours after surgery) inhibited inflammation and gliosis and stimulated both angiogenesis and neurogenesis (Lin et al., 2012). Yang et al. (2014) showed that HBO treatment decreased apoptosis and improved cognitive ability when given 6 hours after TBI in rats. The HBO failed, however, when given 60 days after TBI. Wang et al. (2010) demonstrated that multiple sessions of HBO (3 ATA hourly for 3 or 5 days) are able to extend the therapeutic time window of HBO. Multiple sessions, compared to a single session administered up to 48 hours post-TBI significantly reduced overall neurological deficit scores and neuronal apoptosis (Wang et al., 2010). It has been also demonstrated that HBO enhanced recovery of aerobic metabolic function (Daugherty et al., 2004), increased overall cerebral glucose metabolism (Contreras et al., 1988) and cerebral partial pressure of oxygen (pO2) (Niklas et al., 2004). These results of experimental short-term studies during the acute phase of TBI demonstrated that the beneficial effects of HBO, when the treatment started in early stage after TBI.

At the chronic stage of TBI, HBOT has been showed to improve behavioral and neurobiological outcomes. Repetitive long-term HBOTs (2.5 ATA for 60 minutes daily for 10 days) improved the recovery of motor functions in rats after suction ablation of the right sensorimotor cortex by intensify neuroplastic responses through promoting axonal sprouting and synapse remodeling (Brkic et al., 2012). Moreover, in a rat model of cortical trauma using the focal cortical weight-drop impact method, a 40-day series of HBOTs (1.5 ATA for 90 minutes twice daily) started at 50 days after the initial brain injury, caused an increase in confused hippocampus vascular density and an improvement in cognitive function (Harch et al., 2007). In clinical trials, HBOT was reported to improve sensorimotor functions as well as neuropsychological disorders in chronic TBI patients (Golden et al., 2006; Hardy et al., 2007). These findings affirmed the role of angiogenesis and neurogenesis in function improvement and provided the perspective for implementation of HBO in clinical strategies for treating TBI even at late chronic stages.

**EXPERIMENTAL STUDIES OF HBOT IN TBI**

Researches on HBOT in experimental TBI studies have clarified diverse mechanisms leading to neuroprotection. Many of the pathways work parallel, or together, to induce neuroprotection in the brain. These mechanisms include: 1) increasing tissue oxygenation; 2) reducing inflammation; 3) decreasing apoptosis; 4) reducing ICP; 5) promoting neurogenesis and angiogenesis. For the purpose of this review, a brief summary of the recent discoveries in the mechanism of HBOT will be discussed. Table 1 lists most recent exciting discoveries in animal models, and Figure 1 summarizes the potential mechanisms involved in HBOT.
Table 1: Experimental studies of HBOT in TBI

<table>
<thead>
<tr>
<th>HBO paradigm</th>
<th>Effects</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 ATA for 4 hours</td>
<td>Reduce CSF pressure</td>
<td>Coe and Hayes, 1966</td>
</tr>
<tr>
<td>3 ATA for 45 minutes</td>
<td>Reduce brain edema and decrease mortality</td>
<td>Dunn and Lawson, 1966</td>
</tr>
<tr>
<td>2 ATA for 4 hours</td>
<td>Decrease ICP and CBF</td>
<td>Miller et al., 1970</td>
</tr>
<tr>
<td>2.8 ATA for 45 minutes for two sessions</td>
<td>Decrease apoptosis</td>
<td>Palzur et al., 2004</td>
</tr>
<tr>
<td>2.8 ATA for 45 minutes for two sessions</td>
<td>Decreased apoptosis and preserved mitochondrial membrane properties</td>
<td>Palzur et al., 2008</td>
</tr>
<tr>
<td>2.8 ATA for 45 minutes for two sessions</td>
<td>Reduced inflammation and the expression of matrix metalloproteinase-9</td>
<td>Vlodavsky et al., 2006</td>
</tr>
<tr>
<td>2.0 ATA for 1 hour</td>
<td>Increased interleukin-10, reduced lesion volume and cerebral edema, and improved neurological status</td>
<td>Chen et al., 2014</td>
</tr>
<tr>
<td>3 ATA hourly for 3 or 5 days</td>
<td>Multiple HBO treatment reduced apoptosis and neurological deficits</td>
<td>Daugherty et al., 2004</td>
</tr>
<tr>
<td>1.5/2.5 ATA for 1 hour</td>
<td>Increased brain tissue pO$_2$</td>
<td>Contreras et al., 1988; Brkic et al., 2012</td>
</tr>
<tr>
<td>2 ATA for 90 minutes daily for 4 days</td>
<td>Increased the overall cerebral glucose utilization</td>
<td>Niklas et al., 2004</td>
</tr>
<tr>
<td>2.0 ATA for 60 minutes daily for 3 days</td>
<td>Inhibited inflammation and gliosis, and stimulated both angiogenesis and neurogenesis</td>
<td>Lin et al., 2012</td>
</tr>
<tr>
<td>2.5 ATA for 60 minutes daily for 10 days</td>
<td>Promoted axonal sprouting and synapse remodeling, and improved recovery of motor functions</td>
<td>Harch et al., 2007</td>
</tr>
<tr>
<td>1.5 ATA for 90 minutes twice daily for 40 days</td>
<td>Increased hippocampus vascular density and improved cognitive function</td>
<td>Hardy et al., 2007</td>
</tr>
</tbody>
</table>

Note: HBOT: Hyperbaric oxygen therapy; TBI: traumatic brain injury; HBO: hyperbaric oxygen; ICP: intracranial pressure; CBF: cerebral blood flow; CSF: cerebrospinal fluid; pO$_2$: partial pressure of oxygen. 1 Atmosphere absolute (ATA) = 101.3 kPa.

Table 2: Clinical studies of HBOT in TBI patients

<table>
<thead>
<tr>
<th>HBO paradigm</th>
<th>TBI type</th>
<th>Effects</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0 ATA</td>
<td>Acute TBI</td>
<td>Affected ICP and CBF</td>
<td>Hayakawa et al., 1971; Sukoff and Ragatz, 1982</td>
</tr>
<tr>
<td>1.5–1.75 ATA for 1 hour daily for total 188 treatments with breaks</td>
<td>Closed head injury</td>
<td>Improved grey matter metabolic activity</td>
<td>Neubauer et al., 1994</td>
</tr>
<tr>
<td>1.5 ATA for 35–40 minutes</td>
<td>Brain lesion</td>
<td>Improved glucose metabolism</td>
<td>Holbach et al., 1977</td>
</tr>
<tr>
<td>1.5 ATA for 1–2 hours daily for 3–10 days</td>
<td>Severe TBI</td>
<td>Reduced mortality and improve outcome</td>
<td>Lv et al., 2011; Prakash et al., 2012; Rockswold et al., 2013</td>
</tr>
<tr>
<td>1.25 to 2.5 ATA, twice a week to 12 times a week</td>
<td>Chronic TBI</td>
<td>Improved CBF</td>
<td>Golden et al., 2002</td>
</tr>
<tr>
<td>1.25 to 2.5 ATA, twice a week to 12 times a week</td>
<td>Chronic TBI</td>
<td>Ameliorated the neuropsychological disorders</td>
<td>Golden et al., 2002, 2006</td>
</tr>
<tr>
<td>2 ATA for 1 hour daily for 20 days or 60 days</td>
<td>Chronic TBI</td>
<td>Improved outcome</td>
<td>Holbach et al., 1974</td>
</tr>
<tr>
<td>1.5 ATA for 1 hour, twice a day on weekdays for 1 or 2 months</td>
<td>Post-concussion syndrome</td>
<td>Improved CBF and alleviated post-concussive symptoms</td>
<td>Harch et al., 2009, 2012; Boussi-Gross et al., 2013</td>
</tr>
<tr>
<td>2.5 ATA</td>
<td>Head injury coma</td>
<td>Promoted consciousness recovery</td>
<td>Artru et al., 1976</td>
</tr>
<tr>
<td>1.5 ATA for 1 hour daily until the patient was awake</td>
<td>Closed-head trauma</td>
<td>Did not improve outcome</td>
<td>Rockswold et al., 1992</td>
</tr>
<tr>
<td>2.5 ATA for 40–60 minutes daily for 10 days, 4 sessions with intervals</td>
<td>Severe TBI</td>
<td>Improved outcome, reduced ICP, decreased the mortality and morbidity</td>
<td>Ren et al., 2001a; Mao et al., 2010</td>
</tr>
<tr>
<td>2.5 ATA for 1 hour daily for 10 days</td>
<td>Cranioencephalic injury</td>
<td>Did not improve outcome</td>
<td>Xie et al., 2007</td>
</tr>
<tr>
<td>1.5 or 2.0 ATA for 1 hour daily for 40 treatments in 10 weeks</td>
<td>Post-concussion syndrome</td>
<td>Did not improve outcome</td>
<td>Wolf et al., 2012b; Cifu et al., 2014a, b; Miller et al., 2015</td>
</tr>
</tbody>
</table>

Note: HBOT: Hyperbaric oxygen therapy; TBI: traumatic brain injury; HBO: hyperbaric oxygen; ICP: intracranial pressure; CBF: cerebral blood flow; CSF: cerebrospinal fluid. 1 Atmosphere absolute (ATA) = 101.3 kPa.

2004; Niklas et al., 2004). Results of several studies suggest that increasing brain tissue oxygenation contributed to reduced mortality and improved outcome of TBI patients (Rockswold et al., 2010, 2013).

HBOT increases tissue oxygenation
Henry’s law states that the amount of gas dissolved in a liquid or tissue is proportional to the partial pressure of that gas in contact with the liquid or tissue. This is the basis for increased tissue oxygen tensions with HBO treatment. In physiological condition, most oxygen carried in the blood is bound to hemoglobin, which is 97% saturated at atmospheric pressure. The other oxygen is carried in solution, and this portion is increased with the pressure due to Henry’s Law. When breathing normobaric air, arterial oxygen tension is approximately 100 mmHg, and tissue oxygen tension approximately 55 mmHg. However, 100% oxygen at 3 ATA can increase arterial oxygen tensions to 2,000 mmHg, and tissue oxygen tensions to around 500 mmHg (Ratzenhofer-Komenda et al., 2006). The marked increased oxygen tension gradient from the blood to metabolizing cells is a key mechanism by which hyperoxegenation of arterial blood can improve effective cellular oxygenation even at low rates of tissue blood flow (Thom, 2011). And as the oxygen is in solution, it can reach physically obstructed areas where red blood cells cannot pass. HBO (1.5 ATA for 60 minutes) significantly increases brain tissue oxygen pressure (pO2) in both injured and sham-injured rats (Daugherty et al., 2004; Niklas et al., 2004). Results of several studies suggest that increasing brain tissue oxygenation contributed to reduced mortality and improved outcome of TBI patients (Rockswold et al., 2010, 2013).

HBOT suppresses inflammation
The acute inflammatory response plays an important role in secondary brain damage after TBI, which is characterized by cytokine release, neutrophil activation and microvascular adherence. Reducing inflammation is essential for the treatment of TBI. HBO has been shown to suppress inflammation in many studies (Vlodavsky et al., 2006; Lin et al., 2012; Zhang et al., 2014a; Meng et al., 2016a, b). When healthy humans are exposed to HBO at 2.8 to 3.0 ATA for at least 45 minutes, the ability of circulating neutrophils to adhere to target tissues is temporarily inhibited (Kalns et al., 2002). In a blast-induced traumatic brain injury model in rabbits, HBOT (2 ATA for 60 minutes) administrated at 12 hours after injury reduced the RNA and protein levels of caspase-3, interleukin-8 and tumor necrosis factor-α (Zhang et al., 2014a). In the early stage of TBI in rats, HBOT improved outcomes and reduced inflammation by increasing anti-inflammatory cytokine interleukin-10 (Lin et al., 2012; Chen et al., 2014),
HBOT decreases ICP
Critical elevation of ICP represents the leading cause of morbidity and mortality in patients suffering from severe TBI (Horn et al., 1999). One of the important mechanisms of HBOT for severe brain injury is to lower ICP. Brown et al. (1998) first reported that HBO at 2 ATA for 60 minutes lowered ICP during the first 15 minutes of therapy in head-injured patients, however, rebound elevation were seen during or after therapy (Brown et al., 1988). A definite positive effect of HBOT on ICP was achieved by Rogatsky et al. (2005). HBOT (2.5 ATA for 60 minutes) applied within 24 hours ameliorated the outcome and reduced ICP by decreasing endothelin, improving the blood velocity of middle cerebral artery and decreasing cerebral vascular resistance in severe TBI patients (Ren et al., 2001b). Mechanisms of HBOT reducing ICP can also be related to the subsequent sustained improvement in tissue metabolism of the traumatized brain, as shown by Rockswold et al. (2001). The same conclusion was drawn when applied HBO to rats after severe fluid percussion brain injury. HBOT significantly diminished ICP elevation rate and decreased mortality when HBO was administrated within 2 hours after severe trauma (Rogatsky et al., 2005).

HBOT promotes neurogenesis and angiogenesis
Many studies have reported that multiple HBOT could improve neurological deficits and cognitive impairments at the acute stage (Lin et al., 2012) and at late chronic stages, months to years after TBI (Brown et al., 1988; Contreras et al., 1988; Horn et al., 1999; Ren et al., 2001b; Daugherty et al., 2004; Harch et al., 2007, 2009, 2012; Kernie and Parent, 2010; Brkic et al., 2012; Xu et al., 2012; Boussi-Gross et al., 2013). The therapeutic effects of long-term HBOT may be associated with multifaceted repair, including activation of angiogenesis and triggering of neuroplasticity, and induce proliferation and differentiation of neuronal stem cells. When HBO (2 ATA for 60 minutes twice a day for 3 consecutive days) was given within 3 hours after injury in fluid percussion model of TBI in rats, there was a significant increase in newborn endothelia cells, neurons and glial cells at 4 days after TBI (Lin et al., 2012). Ten exposures of HBO (2.5 ATA for 60 minutes for 10 days) can intensify neuroplastic responses by promoting axonal sprouting and synapse remodeling, which contributes to the recovery of locomotor performances in TBI rats (Brkic et al., 2012); 40-day series of 80 HBOs (1.5 ATA for 90 minutes each time) caused an increase in contused hippocampus vascular density and an associated improvement in cognitive function (Harch et al., 2007). Activation of several signaling pathways and transcription factors have been suggested to play an important role in HBOT-induced neurogenesis, including Wnt, hypoxia-inducible factors and cAMP response element-binding (Mu et al., 2011).

Clinical studies of HBOT in TBI patients
With the sound theoretical underpinning and demonstrated efficacy in experimental studies, intense clinical studies are conducted with the aim of evaluating the efficacy and safety of HBOT in relation to brain injuries and neurological disorders. HBOT in a clinical setting is usually implemented in the form of repetitive sessions over extensive time periods in order to improve neurological outcomes following TBI. Typical treatments involve pressurization to between 1.5 and 3.0 ATA for periods between 60 and 120 minutes, once
or more daily. Treatment may range from less than 1 week to several months' duration, the average being 2 to 4 weeks, depending on the response of the individual patient and the severity of the original problem. The clinical efficiency of HBOT in TBI remains controversial. Since the 1960s, many reports have demonstrated an HBOT-associated reduction in mortalities and/or improvement of neurological functions after TBI (Table 2). However, most are based on case studies or retrospective analyses. Standardized clinical studies reporting HBOT-associated protective effects on TBI mediated brain damage are scarce, and an explicit benefit of HBOT for TBI patients has yet to be established.

The first clinical observation that presented a therapeutic effect of HBOT in TBI patients was carried out by Fasano et al. (1964), in which HBO improved the outcome following brain trauma. HBOT has been shown to change ICP (Hayakawa et al., 1971) and reduce CSF pressure in patients with acute cerebral damage (Hayakawa et al., 1971; Sukoff and Ragatz, 1982), improved grey matter metabolic activity on single-photon emission computerized tomography scan in closed head injury (Neubauer et al., 1994), and improved glucose metabolism after brain injury (Holbach et al., 1977). In severe TBI, HBOT has decreased mortality and improved functional outcome (Lv et al., 2011; Prakash et al., 2012; Rockswold et al., 2013). In chronic brain injury, HBOT improved CBF (Golden et al., 2002), ameliorated the neuropsychological disorders (Golden et al., 2002, 2006), and enhanced neuropsychological and electrophysiological improvements (Holbach et al., 1974). HBOT has also been reported to show positive effects by improving the quality of life in patients with post concussion syndrome or mild TBI at late chronic stage (Harch et al., 2009, 2012; Bousiss-Gross et al., 2013). These cases and studies showed the successful use of intensive HBO as a therapeutic modality in various TBI patients.

However, it should also be noted that there were conflicting results of HBOT in TBI patients. Bennett et al. (2012) reviewed the trials with “HBOT and acute TBI” that published between 1974 and 2010, and analyzed 7 studies involving 571 people. In the seven papers in this review (Holbach et al., 1974; Artru et al., 1976; Rockswold et al., 1992, 2010; Ren et al., 2001a; Xie et al., 2007; Mao et al., 2010), the authors performed Meta-analysis with proportion of participants with an unfavorable functional outcome, mortality, intracranial pressure and improvements in Glasgow Outcome Score, pulmonary effects of HBOT and neurological oxygen toxicity with HBOT. The authors concluded that HBOT showed no evidence in improving life quality after TBI, although the evidence did suggest an improvement in survival (Bennett et al., 2012). In other four studies on HBOT effect on mild TBI or post-concussion syndrome, there was no evidence that supported for routine application of HBOT to mild TBI patients (Wolf et al., 2012b; Cifu et al., 2014a, b; Miller et al., 2015). In these four prospective, randomized studies from Wolf et al. (2012b), Cifu et al. (2014a, b), and Miller et al. (2015), the subjects were U.S. military service members who received 30 to 40 sessions of either a sham or HBO in the treatment of post-concussion syndrome. The results of these studies failed to prove the therapeutic effects of HBO in post concussion syndrome after mild TBI and the authors didn’t recommend HBO for the treatment of post concussion syndrome.

**Issues affect the efficiency of HBOT in TBI**

Currently, the results of HBOT in clinical TBI trials are controversial and the efficiency of HBOT in TBI has not been well established. Here we will discuss the issues that affect the efficiency of HBOT in TBI patients.

First, the optimal time window for HBO administration is one of the crucial facts that determine its efficacy in TBI. The neuroprotective effects of HBO have all been achieved when intervention was administered during the acute phase, within hours after TBI (Palzur et al., 2004, 2008; Vlodavsky et al., 2006; Lin et al., 2012; Rockswold et al., 2013). The prolonged therapeutic time window of HBO was investigated in animal models of TBI. HBO administrated within 6 hours after TBI decreased apoptosis and improved cognitive ability (Yang et al., 2014), and multiple sessions of HBO (3 ATA hourly for 3 or 5 days) could extend the time window up to 48 hours post-TBI (Wang et al., 2010). The data of these pre-clinic and clinic studies indicated that HBO is beneficial when it is applied in the early stage. Application of HBO within a therapeutic time window established in preclinical study is an important requirement the efficiency.

Second, objective and precise assessment methods are another challenge in the evaluation of the efficacy of HBOT in TBI patients. Cognitive, emotional, behavioral, and physical impairments are common sequelae of TBI. In most clinical studies, the outcome was evaluated by neuropsychological tests, such as the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), Neurobehavioral Symptom Inventory and Automated Neuropsychological Assessment Metrics. All the assessments are well established, however, they are all subjective performance evaluations. It is well known that RPQ displays several flaws in its implementation and in its ability to accurately reflect test-taker experience (Potter et al., 2006). Interpretation and accuracy of the RPQ can vary widely due to self-administration and the various confounding variables involved, because it is sensitive to subjective patient memory, social desirability, stress, and other covariates such as personality factors and willingness to reveal problems, as are the two other methods. Relying totally on
the self-administration assessments is a weakness of these studies. More objective assessment methods, such as brain single photon emission computed tomography imaging or electrophysiological measurement may be needed to provide authentic evidences for HBOT or control interventions and to allow a greater refinement of HBOT in TBI.

Third, heterogeneity of the patients and HBO paradigms (pressure, frequency, length of treatment course) partly affect or determine the outcome. There were variations in age of patients, and in severity and nature of the injury in the studies. There is significant preference that HBO showed more efficiency in younger age (He et al., 2005; Lund et al., 2005). And it is possible that HBOT has a positive effect in a subgroup of patients with moderate injury but not in those with extensive cerebral injury. Repetitive long-term HBO treatment following TBI would have more pronounced effects and might modulate different cerebral functions than short-term treatment during the acute phase of TBI only (Kraitsy et al., 2014).

Fourth, HBOT is not a completely benign process and there are concerns about its safety aspects. Possible complications during HBOT include barotraumatic lesions (middle ear, nasal sinuses, inner ear, lung, teeth), oxygen toxicity (central nervous system, lung), confinement anxiety, and ocular effects (myopia, cataract growth) (Camporesi, 2014). The predominant complication is represented by pressure equalization problems within the middle ear, and can be prevented or minimized by teaching autoinflation techniques. Serious complications such as seizures rarely occur and can be controlled by reducing oxygen pressure (Hadanny et al., 2016). Other adverse events such as pulmonary barotrauma and edema derive from oxygen toxicity occur rarely in specific patient cohorts (Wolf et al., 2012a). In conclusion, if safety guidelines are strictly followed, HBOT is a modality with an acceptable rate of complications.

Conclusions

HBOT has been demonstrated to have neuroprotective effects without increased oxygen toxicity in experimental TBI models when administered at pressures less than 3 ATA (Table 1). The improved tissue oxygenation and cellular metabolism, anti-inflammation, anti-apoptosis and promoting neurogenesis and angiogenesis may constitute the multiple and complementary mechanisms underlying HBOT-induced neuroprotection (Figure 1). Due to the heterogeneity of human TBI, the efficacy of clinical HBOT remains controversial (Table 2). Delayed treatment time, subjective methods for outcome measurement, and inappropriate HBO paradigms could contribute to misinterpretation of results and prevent a positive recommendation of HBO in TBI patients. These key factors should be considered in the future clinical studies of HBO in TBI and other neurological diseases.

References


Fifth, there are concerns about its safety aspects. Possible complications during HBOT include barotraumatic lesions (middle ear, nasal sinuses, inner ear, lung, teeth), oxygen toxicity (central nervous system, lung), confinement anxiety, and ocular effects (myopia, cataract growth) (Camporesi, 2014). The predominant complication is represented by pressure equalization problems within the middle ear, and can be prevented or minimized by teaching autoinflation techniques. Serious complications such as seizures rarely occur and can be controlled by reducing oxygen pressure (Hadanny et al., 2016). Other adverse events such as pulmonary barotrauma and edema derive from oxygen toxicity occur rarely in specific patient cohorts (Wolf et al., 2012a). In conclusion, if safety guidelines are strictly followed, HBOT is a modality with an acceptable rate of complications.

Conclusions

HBOT has been demonstrated to have neuroprotective effects without increased oxygen toxicity in experimental TBI models when administered at pressures less than 3 ATA (Table 1). The improved tissue oxygenation and cellular metabolism, anti-inflammation, anti-apoptosis and promoting neurogenesis and angiogenesis may constitute the multiple and complementary mechanisms underlying HBOT-induced neuroprotection (Figure 1). Due to the heterogeneity of human TBI, the efficacy of clinical HBOT remains controversial (Table 2). Delayed treatment time, subjective methods for outcome measurement, and inappropriate HBO paradigms could contribute to misinterpretation of results and prevent a positive recommendation of HBO in TBI patients. These key factors should be considered in the future clinical studies of HBO in TBI and other neurological diseases.

Author contributions

QH write the paper; AM reviewed the studies in animal models; TX and ZG reviewed the studies on clinic. JT and JZ modified the language. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare that there is no completing interest regarding the publication of this paper.


